BioSpace News Archive

Dana-Farber Cancer Institute Joins the Parker Inst

Deals

CombiMatrix Reminds Shareholders to Vote “FOR” the Merger With Invitae

Although 96% of votes cast to date are in favor of the merger, a majority of shares outstanding must vote “for” the transaction.

November 3, 2017

·

9 min read

Business

Pacific Biosciences Appoints Kathy Ordonez as Chief Commercial Officer

Ms. Ordonez brings more than thirty years of experience in the life sciences and diagnostics industries, with senior roles at Hoffmann-La Roche, Celera, Quest Diagnostics and RainDance Technologies.

November 3, 2017

·

3 min read

Business

Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance

For Q3 2017, Total revenues were $149.4 million, an increase of 5% as compared to 2016.

November 3, 2017

·

23 min read

Business

OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights

As of September 30, 2017, cash, cash equivalents and short-term investments totaled $113.6 million.

November 3, 2017

·

10 min read

Drug Development

Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting

Zilretta is a non-opioid medicine that employs Flexion’s proprietary microsphere technology.

November 3, 2017

·

10 min read

Drug Development

ACADIA Pharmaceuticals Presents Data From the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting

Pimavanserin met the primary endpoint in the Phase II -019 Study, showing a statistically significant reduction in psychosis versus placebo, as previously reported.

November 3, 2017

·

12 min read

Business

Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results

Net loss for the quarter ended September 30, 2017 was $3.8 million, or loss per share of $0.29, compared to a net loss of $1.3 million, or loss per share of $0.19, for the third quarter of 2016.

November 3, 2017

·

7 min read

Business

Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results

Adamas reported a net loss of $23.4 million, or $1.04 per share, basic and diluted, for the third quarter of 2017, compared to a net loss of $14.4 million, or $0.66 per share, basic and diluted, for the third quarter of 2016.

November 3, 2017

·

9 min read

Business

Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results

As at September 30, 2017, Arbutus had cash, cash equivalents, short-term investments and restricted investments totaling $100.8 million, as compared to $143.2 million at December 31, 2016.

November 3, 2017

·

19 min read

Business

CluePoints Builds on Late Phase Work in Japan and Launches Risk-Based Monitoring Roadshow in Tokyo

The collaborations mark the latest success for CluePoints in the region, with its centralized statistical monitoring (CSM) platform having already been used by the Nagoya University School of Medicine for an eight-year Phase III Stomach Cancer Adjuvant Multi-Institutional Group Trial (SAMIT).

November 3, 2017

·

3 min read